Literature DB >> 2728925

Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride.

L R Hedlund1, J C Gallagher.   

Abstract

There has been controversy as to whether fluoride therapy increases the risk of fracture in the appendicular skeleton. In the present study we compared the incidence of hip fracture in four groups of osteoporotic women: 22 treated with placebo, 17 with fluoride and calcium, 18 treated with fluoride and calcitriol, and 21 with calcitriol alone. Four hip fractures occurred in 3 patients on fluoride and calcitriol, and two hip fractures occurred in 2 patients on fluoride and calcium. No hip fractures occurred in patients receiving either calcitriol alone or placebo. The difference in fracture rates for fluoride versus nonfluoride treatment is significant (p = 0.006). Moreover, the six hip fractures occurring in patients receiving fluoride during 72.3 patient years of treatment is 10 times higher than would be expected in normal women of the same age. The probability of observing six fractures in 2 years is extremely small (0.0003). In four of the hip fracture cases, the history suggested a spontaneous fracture. These findings suggest that fluoride treatment can increase the risk of hip fracture in osteoporotic women.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2728925     DOI: 10.1002/jbmr.5650040214

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  21 in total

Review 1.  Management of menopause when estrogen cannot be used.

Authors:  R L Young; N S Kumar; J W Goldzieher
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

2.  [Insufficiency fractures in rheumatology. Case report and overview].

Authors:  R Dreher; F Buttgereit; W Demary; B Görtz; G Hein; P Kern; A Schulz
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

Review 3.  A biomechanical perspective on bone quality.

Authors:  C J Hernandez; T M Keaveny
Journal:  Bone       Date:  2006-07-28       Impact factor: 4.398

Review 4.  The pathogenesis and treatment of hip fractures.

Authors:  P Lips; K J Obrant
Journal:  Osteoporos Int       Date:  1991-09       Impact factor: 4.507

5.  What is the future for fluoride in the treatment of osteoporosis?

Authors:  J D Ringe; P J Meunier
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

Review 6.  Strontium ranelate: a novel mode of action leading to renewed bone quality.

Authors:  Patrick Ammann
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

7.  Peak bone mass and osteoporosis prevention.

Authors:  J A Eisman; P J Kelly; N A Morrison; N A Pocock; R Yeoman; J Birmingham; P N Sambrook
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 8.  Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action.

Authors:  B A Dure-Smith; M E Kraenzlin; S M Farley; C R Libanati; E E Schulz; D J Baylink
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 9.  Is fluoride treatment justified today?

Authors:  J A Inkovaara
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 10.  Fluoride therapy of type I osteoporosis.

Authors:  J P Devogelaer; C Nagant de Deuxchaisnes
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.